Psychotic illnesses, such as schizophrenia and bipolar affective disorder, have a combined lifetime prevalence of approximately 3%.
1 The research domain criteria initiative from the National Institute of Mental Health proposes that common neurobiological mechanisms underlie symptom domains across disorders.
2 The neuromodulator dopamine has been implicated in the pathophysiology of psychosis in schizophrenia
3-9 and psychosis in other disorders.
10 Investigations using positron emission tomography (PET) have demonstrated increased striatal dopamine synthesis capacity in schizophrenia.
11 Dopamine synthesis capacity is also elevated in individuals at high clinical risk of psychosis,
12-16 some of whom may develop bipolar affective disorder with psychosis,
17 and in individuals with psychosis in the context of temporal lobe epilepsy.
10 These findings suggest that elevated dopamine synthesis capacity may be transdiagnostic, underlying psychosis across disorders, rather than specific to schizophrenia. Evidence also suggests that dopamine dysfunction increases with development of psychosis
15 and is greater in acute psychosis relative to remission,
9 suggesting a state component.